Four emerging immune cellular blood phenotypes associated with disease duration and activity established in Psoriatic Arthritis

Marie Skougaard¹,²,³*, Sisse B. Ditlev³, Zara R. Stisen¹, Laura C. Coates⁴, Karen Ellegaard¹ and Lars Erik Kristensen¹

Abstract

Background: Psoriatic Arthritis (PsA) is an immune-mediated disease with heterogenous symptoms indicating differences in the underlying immunopathogenesis. The primary objective of the study explored the dynamic mechanisms and interplay between immune cell subtypes constituting the immune response driving PsA to evaluate possible differences in immune cellular phenotypes, and secondary examined associations between emerging immune cellular phenotypes and disease outcomes.

Methods: Peripheral blood was collected from 70 PsA patients. Frequencies of nine immune cell subtypes were determined by multicolor flow cytometry. The interplay between immune cells were examined with principal component analysis (PCA) to establish immune cellular phenotypes. Disease characteristics, Disease Activity in Psoriatic Arthritis (DAPSA) and Psoriasis Area Severity Index (PASI) were retrieved to examine associations to individual cellular phenotypes.

Results: Four components were identified using PCA resembling four immune cellular phenotypes. Component 1, explaining 25.6% of the variance with contribution from T-helper 17 cells (Th17), memory T regulatory cells (mTregs), dendritic cells and monocytes, was associated with longer disease duration and higher DAPSA. Component 2, driven by Th1, naïve Tregs and mTregs, was associated with shorter disease duration. Component 3 was driven by both Th1, Th17 and CD8+ T cells, while component 4 was characterized by a reverse correlation between CD8+ T cells and natural killer cells.

Conclusion: Four immune cellular phenotypes of PsA were suggested at baseline demonstrating complex immune cellular mechanisms in PsA implying the possibility of improving PsA patient stratification based on both clinical and immune cellular phenotypes.

Keywords: Psoriatic Arthritis, Immunophenotyping, Flow cytometry, Principal Component Analysis, T cell
phenotypes observed when comparing PsA patients, and it further indicates the potential heterogeneity in the underlying immune cellular phenotypes. However, differences in immune cellular mechanisms differentiating PsA patients remain poorly understood.

PsA was originally believed to be driven by an autoimmune adaptive immune response [3], which has been challenged by evidence implicating the importance of an ongoing interplay between adaptive and innate mechanisms [4]. Innate immune cells, such as monocytes, are known to differentiate into antigen-presenting cells, including dendritic cells [5], found relevant to PsA due to their ability to secrete interleukin (IL)-12 and IL-23 inducing differentiation of T cells towards subtypes; type 1 and 17 helper T cells (Th1 and Th17) [1, 6]. T cells have been the primary suspects in PsA pathogenesis [7, 8], with IL-23 and IL-17 secreting CD4+ Th17 cells increased in both peripheral blood and synovial fluid [9]. Thus, both innate and adaptive immune cells have been shown to produce and release IL-17 [10] and an accumulation of IL-17 secreting cells has been found in joints of PsA patients and may further include IL-17 secreting CD8+ T cells [11]. T cell subsets, including both Th1, Th17 and CD8+ cytotoxic T (Tc) cells, are known mediators of inflammation in PsA leading to the notion of different immune cellular pathways in PsA [12]. Additionally, individualized treatment strategies targeting individual T cell phenotypes have been suggested [13]. Treatments that may alter immune cellular composition [14, 15], which is reportedly also seen to T-regulatory cells (Tregs) [15]. Tregs were originally considered to prevent chronic inflammation by inducing an anti-inflammatory effect [16]. However, studies on psoriasis and arthritis have revealed contradictory results regarding Treg levels in association with disease activity [17–19].

The dynamic mechanisms between individual immune cells driving PsA immunopathogenesis are complex and clarification is desired to improve patient stratification. Here we present results from an exploratory flow cytometry study assessing the frequencies of nine immune cell subtypes in 70 PsA patients. The primary objective was to assess the interplay between the nine immune cell subtypes to define immune cellular phenotypes in PsA patients, and secondary to explore the associations between emerging phenotypes and clinical outcome measures.

Materials and methods

Study population
Seventy PsA patients were recruited from the Parker Institute’s PsA patient cohort, which comprises an observational cohort study examining the effect of treatment on clinical, para-clinical and patient-reported parameters [20]. All patients participated in a baseline visit adjacent to initiating treatment. Patients were included if fulfilling the CASPAR criteria [19] and initiating new treatment with either Tumour Necrosis Factor alpha inhibitor (TNFi), Interleukin-17 inhibitor (IL-17i) or methotrexate (MTX).

The study was conducted in accordance with the Declaration of Helsinki with ethical approval obtained from the Danish Ethical Committee of the Capital Region of Denmark (J.no.: H-18024568), and the General Data Protection Regulation approved by the Capital Region of Denmark (J.no.: BFH-2015-043). All patients provided written informed consent before inclusion. The study was registered at clinicaltrials.gov (NCT02572700). A prespecified protocol is publicly available at the Parker Institute’s website (www.parkerinst.dk).

Patient involvement
A patient research partner was consulted to review research ideas and study objectives during the project. All results were presented and discussed in lay terms with the patient research partner.

Variables and outcome measures
Clinical outcomes measures, i.e., 66/68 swollen and tender joint count, and patient-reported outcome, i.e., Visual Analog Scale (VAS) patient global and pain, were obtained to retrieve the joint disease composite measure Disease Activity for Psoriatic Arthritis (DAPSA). Additional, clinical outcomes included evaluation of dactylitis (number), Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis, nail psoriasis (number), and Psoriasis Area Severity Index (PASI) was obtained to evaluate the psoriatic skin component.

Preparation of cells
Peripheral blood was collected in EDTA vacutainer tubes (Greiner bio-one, Kremsmünster, Germany) and separated by erythrocyte lysis using Ammonium-Chloride-Potassium lysis (ACK) buffer (Lanza, Walkersville, MU USA) to obtain buffy coat. Buffy coat was cryopreserved in heat-inactivated fetal bovine serum (FBS) (Gibco, Grand Island, NY USA) with 10% dimethysulphoxide (DMSO) (ITW Reagents, Darmstedt, Germany). Controlled freezing to -80 °C was ensured with CoolCell™ (Corning) cryogenic storage box and subsequently transferred to liquid nitrogen for longtime storage.

Flow cytometry
Buffy coat was thawed and washed twice in RPMI (Gibco, Parsley, UK) with 10% FBS. Cell solution was diluted to aliquots of 1x10⁶ cells.
Staining panels (Additional file 1) were adapted to local conditions from the Human Immunology Project [21]. The quantity of nine immune cell subtypes, defined by their cell surface markers, were evaluated; CD3+CD8+, T cells, CD3+CD4+CXCR3+CCR6-Th1 cells, CD3+CD4+CXCR3-CCR6+Th17 cells, CD4+CD25+CD127lowCD45RO-naive Tregs (nTregs), CD4+CD25+CD127lowCD45RO+HLA-DR-Unactivated Memory Tregs (umTregs), CD4+CD25+CD127lowCD45RO+HLA-DR+Activated Memory Tregs (amTreg), CD3-CD19-CD20-CD14-HLA-DR+ dendritic cells, CD3-CD19-CD20-CD14-CD16+ Natural killer cells (NK cells), and CD3-CD19-CD14+Monocytes. Flow cytometry was conducted on the Beckman Coulter Gallios with three lasers and a 10-colours configuration. Gating strategy was established, and data was analyzed with Kaluza software for Gallios (Additional file 2).

Statistical analysis
Patient characteristics were presented as medians with interquartile range (IQR) for continuous variables and numbers with percentages for categorical variables. To justify the comparison of cell populations from three staining panels, cell frequency was given as the percentage of the lymphocyte population, which were defined by forward/side scatter plot analyzed under the same circumstances. Principal component analysis (PCA) was incorporated for dimensionality reduction exploring the variance and correlation between evaluated immune cells at baseline. PCA is a well-established method for investigating phenotypes on both the clinical and molecular levels [22, 23]. The number of components included for interpretation was decided by the Kaiser criterion, including components with eigenvalues > 1.0 [24]. The contribution of individual immune cell subtypes to the component was considered important if being above the expected average contribution for all cell types (~11.1%). Component coefficients were evaluated for cell subtypes of importance. Component coefficients >0.50 were considered strong. Five ancillary PCAs were implemented as sensitivity analyses evaluating components when stratifying PsA patients by 1) type of treatment, i.e. TNFi, IL-17i and MTX and 2) clinical phenotype, i.e. PsA with concurrent psoriasis and PsA without psoriasis. Evaluating the secondary objective, patients were stratified by their median contribution to the component to evaluate differences in clinical outcomes between groups. Kruskal-Wallis test was applied to compare treatment groups, i.e., TNFi, IL-17i and MTX. Mann-Whitney U-test was included for the comparison of patient groups below and above the contribution median, respectively. Two-sided p-values <0.05 were considered statistically significant. Statistical analysis was carried out using R Statistics with additional package factoextra.

Results
Seventy PsA patients initiating TNFi, IL-17i or MTX were included. No statistically significant differences were found at baseline comparing the three treatment groups with regards to age, sex, disease duration and clinical outcomes (Table 1). Statistically significant differences were found between groups comparing previous biological disease modifying anti-rheumatic drug (bDMARD) treatment and concomitant conventional synthetic DMARD (csDMARD).

Four independent immune cellular phenotypes are defined in the PCA
Four components, explaining 66.5% of the variance in the dataset, were derived from the evaluation of eigenvalues. Component 1 contributed to 25.6% of the explained variance with Th17 cells, amTregs, umTregs, dendritic cells and monocytes as cell types of importance and main drivers of the component with contribution ≥11.1% and all with strong negative component coefficients (Table 2).

Component 2, explaining 18.4% of the variance, was compared to Component 1 oppositely driven by Th1 cells, nTregs, umTregs and monocytes, thus with only Th1 cells and nTregs reaching a strong correlation (-0.65 and -0.73, respectively). Tc cells, Th1 cells and Th17 cells were considered important contributors to Component 3 that explained 12.5% of the variance. Only the Tc cells were strongly correlated to the component. Component 4 explained 10.0% of the total variance and was driven by CD8+ T cells and NK cells that were reversely correlated (0.61 and -0.59, respectively) (Table 2).

Associations between disease outcome measures and individual components
Comparing patients based on median contribution to the component demonstrated statistically significant differences between groups (Table 3). Assessing Component 1 revealed that PsA patients above-median contribution (0.708) had statistically significant higher DAPSA at baseline (median 37.20 [IQR; 25.80-42.10], p=0.004), longer disease duration (9.50 [1.92-15.71], p=0.014), and higher enthesitis score (median 5.00 [3.00-7.00], p<0.001) compared to patients with low contribution to the component (DAPSA 24.90 [19.15-36.40], disease duration 2.67 [1.92-5.21], enthesitis score (1.00 [0.00-3.00]). However, with statistically significant lower number of nails with psoriasis. Comparing patient groups associated with Component 2 demonstrated statistically significant difference in disease duration including patients with...
contribution to the component \( \geq \text{median} \) (0.713) having shorter disease duration (3.00 [1.00-8.13], \( p = 0.039 \)). No statistically significant differences were found comparing groups of Component 3, while statistically significant differences were found comparing PASI in Component 4 with lower PASI for the high contribution group (PASI 0.85 [0.00-1.58], \( p = 0.046 \)).

Similar immune cellular phenotypes emerged stratifying by treatment group

90% of PsA patients initiating MTX were bio-naïve, i.e., patients had not received any immunosuppressives with an assumed effect on the inflammatory immune response. Four components were included for analysis, explaining a total of 79.8% of the variance in the dataset comprising MTX initiators. In line with the primary analysis, the first component (29.3%) was driven by strongly correlated cells, Th17 cells (-0.66), amTregs (-0.88), umTregs (-0.76) and dendritic cells (-0.70), while the second component constituted 22.0% of the variance comprised correlated Tc cells (0.51), Th1 cells (0.80) and Th17 cells (0.52). Additionally, the fourth component was driven by Tc cells with contribution from umTregs, the last of which was not strongly correlated to Component 4 (Table 4). The results establish the importance of the proposed immune cellular phenotypes in PsA. Minor

### Table 1 Patient characteristics

|                          | All (n=70) | TNFi (n=30) | IL17 (n=20) | MTX (n=20) | p-value |
|--------------------------|------------|-------------|-------------|------------|---------|
| Female                   | 39 (55.71) | 17 (56.67)  | 12 (60.00)  | 10 (50.00) | 0.811   |
| Age, years               | 51.50 [45.23-61.23] | 49.25 [41.83-59.12] | 50.15 [45.17-61.95] | 56.80 [51.35-62.38] | 0.133   |
| Disease duration, years  | 4.00 [1.58-10.00] | 3.67 [1.56-8.31] | 7.75 [1.65-14.25] | 3.13 [1.44-10.75] | 0.645   |

**Treatment**

Previous bDMARD

|                | All (n=70) | TNFi (n=30) | IL17 (n=20) | MTX (n=20) | p-value |
|----------------|------------|-------------|-------------|------------|---------|
| Bio-naive      | 40 (57.14) | 20 (66.67)  | 2 (10.00)   | 18 (90.00) | < 0.001 |
| 1              | 15 (21.43) | 7 (23.33)   | 6 (30.00)   | 2 (10.00)  |         |
| 2              | 8 (11.43)  | 2 (6.67)    | 6 (30.00)   | 0 (0.00)   |         |
| 3              | 3 (4.29)   | 0 (0.00)    | 3 (15.00)   | 0 (0.00)   |         |
| 4              | 3 (4.29)   | 1 (3.33)    | 2 (10.00)   | 0 (0.00)   |         |
| 5              | 1 (1.43)   | 0 (0.00)    | 1 (5.00)    | 0 (0.00)   |         |

Concomitant csDMARD

|                | All (n=70) | TNFi (n=30) | IL17 (n=20) | MTX (n=20) | p-value |
|----------------|------------|-------------|-------------|------------|---------|
| DAPSA          | 29.20 [21.80-39.90] | 27.90 [21.85-39.73] | 36.70 [26.00-47.45] | 27.55 [20.50-36.83] | 0.187   |
| PASI           | 1.20 [0.00-3.30]  | 1.50 [0.30-3.40]  | 0.08 [0.00-2.83]   | 0.95 [0.00-2.93]   | 0.570   |
| PsA without psoriasis | 22 (31.43) | 8 (26.67)   | 8 (40.00)   | 6 (30.00)   | 0.469   |
| Dactylitis     | 16 (22.86) | 6 (20.00)   | 6 (30.00)   | 4 (20.00)   | 0.869   |
| Enthesitis     | 54 (77.14) | 24 (80.00)  | 16 (80.00)  | 14 (70.00)  | 0.553   |
| Nail psoriasis | 43 (61.43) | 19 (63.33)  | 10 (50.00)  | 14 (70.00)  | 0.383   |

**Immune cellular frequency**

|                          | All (n=70) | TNFi (n=30) | IL17 (n=20) | MTX (n=20) | p-value |
|--------------------------|------------|-------------|-------------|------------|---------|
| CD8+ T cells, %          | 19.98 [15.12-25.27] | 21.02 [18.63-25.76] | 18.51 [13.14-23.44] | 17.70 [14.96-23.11] | 0.086   |
| Th1 cells, %             | 1.79 [1.28-2.96]  | 1.79 [1.50-3.43]  | 2.25 [1.48-2.94]   | 1.44 [1.05-2.47]   | 0.239   |
| Th17 cells, %            | 3.32 [2.40-4.61]  | 3.25 [2.45-4.50]  | 3.73 [3.09-5.03]   | 2.81 [2.29-3.36]   | 0.089   |
| nTregs, %                | 1.21 [0.87-1.48]  | 1.22 [0.98-1.56]  | 1.13 [0.78-1.50]   | 1.24 [0.82-1.44]   | 0.773   |
| umTregs, %               | 1.13 [0.89-1.50]  | 1.13 [0.95-1.42]  | 1.23 [0.86-1.62]   | 1.07 [0.79-1.56]   | 0.942   |
| amTregs, %               | 0.38 [0.22-0.57]  | 0.36 [0.23-0.58]  | 0.51 [0.21-0.63]   | 0.36 [0.25-0.49]   | 0.760   |
| Dendritic cells, %       | 1.21 [0.76-1.82]  | 1.30 [0.77-1.59]  | 1.18 [0.79-1.86]   | 1.10 [0.72-2.18]   | 0.900   |
| NK cells, %              | 7.42 [5.04-9.69]  | 6.87 [5.16-9.18]  | 5.80 [4.00-6.89]   | 9.14 [6.07-11.41]  | 0.186   |
| Monocytes, %             | 3.79 [2.08-5.41]  | 3.66 [2.03-4.85]  | 3.50 [2.11-5.13]   | 4.03 [3.41-8.13]   | 0.352   |

Patient demographics and treatment characteristics were presented as medians with corresponding interquartile range (IQR) for continuous variables and number of patients with corresponding percentage for categorical variables. Immune cellular frequencies were given as the median percentage of the lymphocyte population with corresponding IQR

bDMARD biological Disease Modifying Anti-rheumatic Drug, csDMARD conventional synthetic Disease Modifying Anti-Rheumatic Drug, DAPSA Disease Activity for Psoriatic Arthritis, PASI Psoriasis Area and Severity Index, Th T helper, nTregs naïve T regulatory cells, umTregs unactivated memory T regulatory cells, amTregs Activated Memory Tregs, NK cells Natural Killer cells
differences were seen evaluating principal components of PsA patients initiating immunosuppressives, i.e., TNFi and IL-17i initiators. Components of TNFi initiators implied shared contributions from multiple immune cell types, while principal components of IL-17i initiators resembled phenotypes of the primary analysis and MTX initiators (Additional files 3 and 4).

Deciphering PsA clinical heterogeneity by immune cellular phenotyping

Two PsA clinical phenotypes were defined as A) PsA patients with psoriasis (n = 48, PASI >0) and B) PsA patients without psoriasis (n = 22, PASI = 0). Four components were included for further analysis during the PCA (Additional files 5 and 6). Components explained a total of 67.8% and 81.4% of the variance in PsA patients with and without psoriasis, respectively. The two different clinical phenotypes (A and B) revealed similarities on the immune cellular level, with Component 1 constituting A) 27.2% and B) 31.0% of the variance defined by strong contribution from correlated cells Th17 (A: -0.56, B: -0.46), amTregs (A: -0.69, B: -0.76), unactivated memory T regulatory cells (A: -0.67, B: -0.77), and dendritic cells (A: -0.54, B: -0.71). However, additional contribution was seen from strongly correlated monocytes to Component 1 in PsA patients with psoriasis (A: -0.55). Component 2 explained A) 16.6% and B) 25.4% of the variance with strong contribution from Th1 cells in both categories. However, Th1 cells did not exhibit strong correlation to other cells of Component 2 in PsA patients without psoriasis, i.e., Th1 (B: -0.76), nTregs (B: -0.82) and umTregs (B: -0.52), and not in PsA patients with psoriasis. Component 3 was driven by strongly correlated cells Tc (-0.53) and Th1 cells (-0.62) in PsA patients with psoriasis and oppositely correlated NK cells (0.57) and monocytes (-0.53) in PsA patients without psoriasis. In contrast, only NK cells (-0.51) and Tc (-0.74) contributed with strong correlation to Component 4 in PsA patients with and without psoriasis, respectively (Additional files 5 and 6).

Discussion

The study aimed to assess immune cell characteristics evaluating possible differences in cellular phenotypes in PsA patients initiating new medical therapy. Comparing treatment groups, statistically significant differences were only found when comparing concomitant csDMARDs and number of previous bDMARDs. This, together with the observed difference in IL-17i initiators’ disease duration compared to TNFi and MTX initiators, may be explained by Danish treatment guidelines that include TNFi being first line bDMARD after csDMARD failure, while IL-17i would be considered after TNFi - unless TNFi was considered contraindicated.

The primary PCA demonstrated strong correlation between immune cell types resembling four immune cellular phenotypes in PsA. The four independent principal components of the PCA, i.e., four phenotypes were established demonstrating complex interplay between immune cells varying together might correspond to immune blood phenotypes in PsA. Patients with high contribution to Component 1, defined by the contribution of Th17, nTregs, dendritic cells and monocytes, had statistically significant longer disease duration and higher disease activity. Compared to patients contributing to

### Table 2 Results from the Principal Component Analyses

| Component | Contribution of individual cell type to the component (%) | Coefficients with correlation between cells type and components |
|-----------|----------------------------------------------------------|-------------------------------------------------------------|
| 1         | 2  | 3  | 4  | 1  | 2  | 3  | 4  |
| Tc cells  | 2.35 | 1.32 | 39.04 | 41.08 | -0.23 | 0.15 | -0.66 | 0.61 |
| Th1 cells | 0.34 | 25.46 | 19.09 | 0.80 | -0.09 | -0.65 | -0.46 | -0.08 |
| Th17 cells | 13.66 | 0.23 | 13.48 | 7.21 | -0.56 | 0.06 | -0.39 | -0.25 |
| nTregs    | 0.07 | 32.39 | 0.15 | 0.01 | 0.04 | -0.73 | 0.04 | -0.01 |
| amTregs   | 25.31 | 4.81 | 7.57 | 0.03 | -0.76 | -0.28 | 0.29 | -0.02 |
| umTregs   | 20.66 | 13.33 | 5.55 | 1.18 | -0.69 | -0.47 | 0.24 | 0.10 |
| Dendritic cells | 18.88 | 1.79 | 0.64 | 0.08 | -0.66 | 0.17 | -0.08 | 0.03 |
| NK cells  | 7.49 | 8.42 | 4.59 | 39.46 | -0.42 | 0.37 | -0.23 | -0.59 |
| Monocytes | 11.24 | 12.26 | 9.89 | 10.14 | -0.51 | 0.45 | 0.33 | 0.30 |

Important contribution to the component was defined as contribution above the average ~11.1%. Correlation coefficients >0.50 were considered strong. Bold text represent values of important contribution and strong correlation coefficients, respectively.

Tc CD8+ cytotoxic T cells, Th1 T helper cell type 1, Th17 T helper cell type 17, nTregs naïve T regulatory cells, amTregs activated memory T regulatory cells, umTregs unactivated memory T regulatory cells, NK cells natural killer cells.
Component 2, characterized by the contribution of Th1 and nTregs, who demonstrated significantly shorter disease duration, this may indicate two pathways including an early Th1 driven disease state and an established Th17 driven disease state with sustained inflammation and high disease activity in this patient cohort. This is supported by previous research reporting higher concentration of CXCL10, a chemokine known to recruit Th1 through CXCL3 [25] in PsA patients with early disease [26], and Th17 cells with reported strong correlation to disease activity together with their importance to both early and established PsA [27]. To fully understand the function of Tregs in this context, e.g. the association between nTregs to Th1 compared to the association between mTregs to Th17 in relation to patient characteristics, it is believed that further Treg subtyping is necessary. Component 3 resembles an immune cellular pathway of PsA including equal contribution of Th1 and Th17 previously described [13] though the strong correlation found with concomitant Tc cells is not well-defined. It may be hypothesized that IFNγ- and/or IL-17-producing Tc cells, found increased in PsA [28, 29], function in the correlating signaling pathway with Th1/Th17 to promote and sustain inflammatory arthritis. As for Tregs, further subtyping may be necessary in relation to the reverse relationship between Tc cells and NK cells observed in Component 4 that indicates the importance of Tc cells independent of Th1/Th17 influence in PsA. Overall, strong component coefficients demonstrate the strong correlation of individual immune cellular blood phenotypes in PsA. Different genotypes have been proposed to determine clinical phenotype [30] supporting the idea of differences in immune cellular phenotypes as well. However, it was not possible to demonstrate a clear

| Component 1 | ≥ median contribution (0.708) | < median contribution (0.708) | p-value |
|-------------|----------------------------|----------------------------|---------|
| Age         | 51.70 (45.40-60.10)         | 51.30 (45.00-62.80)         | 0.573   |
| Disease duration, years | 9.50 (1.92-15.71) | 2.67 (1.92-5.21) | 0.004   |
| DAPSA       | 37.20 (25.80-42.10)         | 24.90 (19.15-36.40)         | 0.014   |
| PASI        | 0.85 (0.00-3.60)            | 1.50 (0.40-3.15)            | 0.355   |
| Dactylitis  | 0.00 (0.00-0.00)            | 0.00 (0.00-0.00)            | 0.948   |
| Enthesitis  | 5.00 (3.00-7.00)            | 1.00 (0.00-3.00)            | <0.001  |
| Nail psoriasis | 0.50 (0.00-6.00) | 4.00 (1.00-8.00) | 0.025   |

| Component 2 | ≥ median contribution (0.713) | < median contribution (0.713) | p-value |
|-------------|----------------------------|----------------------------|---------|
| Age         | 51.20 (40.80-60.55)         | 51.70 (45.40-61.50)         | 0.5809  |
| Disease duration, years | 3.00 (1.00-8.13) | 5.83 (2.29-15.21) | 0.039   |
| DAPSA       | 32.30 (22.35-41.25)         | 28.90 (19.73-39.30)         | 0.418   |
| PASI        | 1.05 (0.00-3.55)            | 1.20 (0.00-2.95)            | 0.900   |
| Dactylitis  | 0.00 (0.00-1.00)            | 0.00 (0.00-0.00)            | 0.521   |
| Enthesitis  | 3.00 (1.00-5.00)            | 3.00 (1.00-5.00)            | 0.749   |
| Nail psoriasis | 2.00 (0.00-5.00) | 4.00 (0.00-8.00) | 0.215   |

| Component 3 | ≥ median contribution (0.655) | < median contribution (0.655) | p-value |
|-------------|----------------------------|----------------------------|---------|
| Age         | 50.50 (42.40-59.20)         | 54.10 (46.40-62.10)         | 0.192   |
| Disease duration, years | 4.00 (2.13-10.00) | 3.42 (1.00-12.13) | 0.530   |
| DAPSA       | 32.30 (23.45-39.70)         | 26.20 (20.93-41.15)         | 0.653   |
| PASI        | 1.30 (0.00-3.23)            | 1.20 (0.00-3.00)            | 0.765   |
| Dactylitis  | 0.00 (0.00-0.00)            | 0.00 (0.00-1.00)            | 0.569   |
| Enthesitis  | 3.00 (0.00-5.00)            | 3.00 (1.00-6.00)            | 0.749   |
| Nail psoriasis | 3.00 (0.00-7.00) | 3.00 (0.00-7.00) | 0.978   |

| Component 4 | ≥ median contribution (0.579) | < median contribution (0.579) | p-value |
|-------------|----------------------------|----------------------------|---------|
| Age         | 51.70 (45.00-61.05)         | 51.30 (46.40-61.00)         | 0.846   |
| Disease duration, years | 3.42 (1.54-10.00) | 4.00 (1.58-13.13) | 0.703   |
| DAPSA       | 31.05 (21.25-41.42)         | 29.00 (21.90-38.55)         | 0.824   |
| PASI        | 0.85 (0.00-1.58)            | 2.00 (0.20-5.00)            | 0.046   |
| Dactylitis  | 0.00 (0.00-0.00)            | 0.00 (0.00-0.00)            | 0.935   |
| Enthesitis  | 3.00 (0.00-5.00)            | 3.00 (1.00-5.00)            | 0.767   |
| Nail psoriasis | 3.00 (1.00-8.00) | 1.00 (0.00-5.00) | 0.191   |

PsA Psoriatic Arthritis, PCA Principal Component Analysis, DAPSA Disease Activity for Psoriatic Arthritis, PASI Psoriasis Area Severity Index
distinction in immune cellular characteristics comparing clinical phenotypes, i.e., PsA patients with and without psoriasis. Though, results did show that Tc cells and monocytes were more significant contributors to components in PsA patients with psoriasis, whereas Th1 and NK cells seemed more important in PsA patients without psoriasis. However, larger studies including clinical homogeneous populations are needed to focus on and understand the immune cellular differences in different PsA clinical phenotypes. Due to the assumption that all immunosuppressive treatments would alter the immune response ancillary PCAs were performed stratifying by type of treatment. The findings supported the primary PCA by implying the importance of immune cell phenotypes comprised by 1) Th17 cells, nTregs and dendritic cells and 2) Tc, Th1, Th17 and NK cells in treatment naïve PsA patients, i.e. PsA patients with an ongoing inflammatory immune response that have not been modulated by medical therapies. Moreover, the ancillary PCAs demonstrated the importance of acknowledging that all treatments induce a yet poorly understood modulation of the inflammatory immune response. However, PCA including only IL-17i initiators that had experienced more therapy switching and suffered from continued high disease activity revealed immune cellular phenotypes resembling that of treatment naïve PsA patients.

The limitations of the study include that 90% of included IL-17i initiators had received other bDMARDs prior to initiation, which most likely have had an immune-modulatory effect compared to bio-naïve patients. Results are still considered of uttermost interest as these patients had high PsA disease activity with no difference to MTX and TNFi initiators. It may further be considered that immune-modulatory response to treatment may be dependent on the generic drug type used. In the current study 19 initiated adalimumab, 1 initiated certolizumab while 5 and 15 patients initiated secukinumab and ixekizumab, respectively, that have known different molecular properties causing diversity due to drug affinity [31, 32]. Moreover, immune cell frequencies were examined in peripheral blood which are known to differ, though, mirroring the immune milieu of inflammatory tissue [33]. As immune cellular milieu also differ comparing joint and skin [34], blood is considered to represent the immune milieu of both tissues. Moreover, additional cell subtyping of Tregs, T cells, monocytes etc. to address cell functionality including methods to evaluate cytokines or gene expression may add further important knowledge [35]. Still, it is believed that results from the current study provide valuable knowledge of immune cellular mechanisms in PsA and the different stages of disease.

### Conclusion

Immune cellular characteristics are complex and in-depth analysis of immune cell subtypes and interplay in PsA is needed to further understand the complex interdependence of immune cells in PsA immunopathogenesis. Results further add to the discussion of stratified treatment based on immune cellular phenotypes. However, additional understanding of immune cellular response mechanisms in larger cohorts is needed before treatment targeting individual immune cellular phenotypes will be possible.

### Table 4

**Results from the Principal Component Analyses including MTX initiators**

| Component | MTX Initiators | Coefficients with correlation between cells type and components |
|-----------|----------------|----------------------------------------------------------------|
| Component 1 | MTX methotrexate, Tc CD8+ cytotoxic T cells, Th1 T helper cell type 1, Th17 T helper cell type 17, nTregs naïve T regulatory cells, amTregs activated memory T regulatory cells, umTregs unactivated memory T regulatory cells, NK cells natural killer cells |
| Tc cells | 4.05 | 0.33 |
| Th1 cells | 0.03 | -0.03 |
| Th17 cells | 16.44 | -0.66 |
| nTregs | 4.04 | -0.32 |
| amTregs | 29.69 | -0.88 |
| umTregs | 21.94 | -0.76 |
| Dendritic cells | 18.77 | -0.70 |
| NK cells | 0.05 | -0.04 |
| Monocytes | 5.00 | -0.36 |

| Component 2 | 13.03 | 0.51 |
| Component 3 | 3.16 | -0.22 |
| Component 4 | 47.33 | 0.69 |

**Important contribution to the component was defined as contribution above the average ~11.1%. Correlation coefficients $\geq 0.50$ were considered strong. Bold text represents values of important contribution and strong correlation coefficients, respectively.**
Supplementary Information

We wish to acknowledge all patients participating in this study, our patient research partner Dorte Kongshøj Marcussen for valuable talks during the project and data manager Christian Cato Holm from the Parker Institute for the assistance during collection and retrieval of data to conduct the study.

Authors’ contributions
All authors participated equally in conceptualizing the project idea and planning the project. MS, ZRS and KE conducted the clinical and paraclinical examination of patients. MS performed the flow cytometry, drafted the protocol and manuscript. All authors participated in the interpretation of results and revised the manuscript. All authors have read and approved the final manuscript.

Funding
This work was supported by an Investigator Initiated Research grant from Lilly, Elisabeth and Karl Ejnar Nis-Hanssens Mindelegat, Minister Erna Hamiltons Legat, and Overlæge Johan Boserup og Lise Boserups Legat. The study is further supported by an unrestricted core grant to the Parker Institute from the Oak Foundation (OCAY-18-774-OPIL).

Availability of data and materials
The data underlying this article cannot be shared publicly due to the privacy of the individuals that participated in the study. Data may be shared as part of research collaborations between participating institutions in line with GDPR of the individuals that participated in the study. Data may be shared as part of research collaborations between participating institutions in line with GDPR and if approved by the Parker Institute and Danish authorities.

Declarations

Ethics approval and consent to participate
The study was conducted in accordance with the Declaration of Helsinki with ethical approval obtained from the Danish Ethical Committee of the Capital Region of Denmark (J.No.: H-18024568), and the General Data Protection Regulation approved by the Capital Region of Denmark (J.no.: BFH-2015-043). All patients provided written informed consent before inclusion. The Parker Institute’s PsA patient cohort study was registered at clinicaltrials.gov (NCT02572700). A pre-specified protocol is publicly available at the Parker Institute’s website (www.parkerinst.dk).

Competing interests
Marie Skougaard has received research funding from, the Danish Rheumatism Association, the Danish National Psoriasis Foundation, and Pfizer that is besides the funding already disclosed under funding
Sisse B. Dittev has no conflicts of interest
Zara R. Stisen has no conflicts of interest
Laura C. Coates has received honoraria, grant/research support or consulting fees from AbbVie, Amgen, Boehringer-Ingelheim, BMS, Celgene, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Sun Pharma, and UCB; and is a member of a speakers’ bureau for AbbVie, Amgen, Biogen, BMS, Celgene, Eli Lilly, Janssen, Medac, Novartis, Pfizer, Sun Pharma, and UCB
Karen Ellegaard has no conflicts of interest
Lars Erik Kristensen has received fees for speaking and consultancy from AbbVie, Amgen, Biogen, Bristol Myers Squibb, Eli Lilly, Gilead, Janssen, MSD, Novartis, Pfizer, and UCB. And IIT grants from Biogen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB.

Author details
1 The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark. 2 Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark. 3 Copenhagen Center for Translational Research, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark. 4 Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.

Received: 24 January 2022 Accepted: 15 November 2022

References
1. Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391(10136):2273–84.
2. Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Hellerspiel P, Boehncke WH, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68(9):1387–94.
3. McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3(8):1242–8.
4. McGonagle D. Enthesitis: An autoimmune inflammatory lesion linking nail and joint involvement in psoriatic disease. J Eur Acad Dermatol Venereol. 2009;23(SUPPL. 1):9–13.
5. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science (80- ). 2010;327(5966):656–61.
6. Qu N, Xu M, Mizoguchi I, Furusawa J, Kanoke K, Watanabe K, et al. Pivotal Roles of T-Helper 17-Related Cytokines, IL-17, IL-22, and IL-23, in Inflammatory Diseases. Clin Dev Immunol. 2013;2013(968549):1–13.
7. Veale DJ, Ritchlin C, FitzGerald O. Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis. 2005;64(SUPPL. 2):26–9.
8. Diann M, Altmoré G, Reali E. T cell responses in psoriatic and psoriatic arthritis. Autoimmun Rev. 2015;14(4):286–92.
9. Kirkham BW, Kavanaugh A, Reich K. Interleukin-17A. A unique pathway in immune-mediated diseases: Psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology. 2014;141(2):133–42.
10. Rosine N, Miceli-Richard C. Innate Cells: The Alternative Source of IL-17 in Axial immune-mediated diseases. PLoS Med. 2006;3(8):1242–8.
11. Menon B, Gullick N, Walter GJ, Rajasekhar M, Garood T, Evans HG, et al. Interleukin-17+CD4+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheum. 2014;66(5):1272–81.
12. Jendr D, Stober C, Pennington SR, FitzGerald O. Applying precision medicine to unmet clinical needs in psoriatic disease. Nat Rev Rheumatol. 2020;16(11):609–27.
13. Miyagawa I, Nakayamada S, Nakano K, Kubo S, Iwata S, Miyazaki Y, et al. Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis. Rheumatol (United Kingdom). 2019;58(2):336–44.
14. Hull DN, Williams RO, Pathan E, Ababin S, Abraham S, Taylor PC. Anti-Humour nerosis factor treatment increases circulating T helper type 17 cells similarly in different types of inflammatory arthritis. Clin Exp Immunol. 2015;181(3):401–6.
15. Mehta H, Mashiko S, Angsana J, Rubio M, Hsieh YCM, Maari C, et al. Differential Changes in Inflammatory Mononuclear Phagocyte and T-Cell
Profiles within Psoriatic Skin during Treatment with Guselkumab vs. Secukinumab. J Invest Dermatol. 2021;141(7):1707–18.

16. Liu Y, Janjour W, Olsen N, Zheng SG. Traitor or warrior--Treg cells sneaking into the lesions of psoriatic arthritis. Clin Immunol. 2020;215(March):108425.

17. Kawashiri SY, Kawakami A, Okada A, Koga T, Tamai M, Yamasaki S, et al. CD4+CD25 highCD127 low/Treg cell frequency from peripheral blood correlates with disease activity in patients with rheumatoid arthritis. J Rheumatol. 2011;38(12):2517–21.

18. Yun WJ, Lee DW, Chang SE, Yoon GS, Huh JR, Won CH, et al. Role of CD4+CD25high+FoxP3+ regulatory T cells in psoriasis. Ann Dermatol. 2010;22(4):397–403.

19. Sugiyama H, Gyuilro R, Toichi E, Shimada S, Stevens SR, et al. Dys-functional Blood and Target Tissue CD4 +CD25 high Regulatory T Cells in Psoriasis: Mechanism Underlying Unrestrained Pathogenic Effector T Cell Proliferation. J Immunol. 2005;174(1):164–73.

20. Høgaard P, Ellegaard K, Nielsen SM, Christensen R, Guldberg-Møller J, Ballegaard C, et al. Pain Mechanisms and Ultrasonic Inflammatory Activity as Prognostic Factors in Patients With Psoriatic Arthritis: A Prospective Cohort Study. Arthritis Care Res. 2019;71(6):798–810.

21. Maeker HT, McCoy JP, Nussenblatt R. Standardizing immunophenotyping for the Human Immunology Project. Nat Rev Immunol. 2012;12(3):191–200.

22. Ye W, Lu W, Tang Y, Chen G, Li X, Ji C, et al. Identification of COVID-19 Clinical Phenotypes by Principal Component Analysis-Based Cluster Analysis. Front Med. 2020;7(November):1–7.

23. Yoon HJ, Kang J, Park H, Sohn I, Lee SH, Lee HY. Deciphering the tumor microenvironment through radiomics in non-small cell lung cancer: Correlation with immune profiles. PLoS One. 2020;15(4):1–13.

24. Peres-Neto PR, Jackson DA, Somers KM. How many principal components? stopping rules for determining the number of non-trivial axes revisited. Comput Stat Data Anal. 2005;49(4):974–97.

25. Lee JH, Kim B, Jin WJ, Kim HH, Ha H, Lee ZH. Pathogenic roles of CXCL10 signaling through CXCR3 and TLR4 in macrophages and T cells: relevance for arthritis. Arthritis Res Ther. 2017;19(1):1–14.

26. Antonielli A, Fallahi P, Delie Sedie A, Ferrari SM, Maccheroni M, Bombardieri S, et al. High values of TH1 (CXCL10) and TH2 (CCL2) chemokines in patients with psoriatic arthritis. Clin Exp Rheumatol. 2009;27(1):22–7.

27. Leipe J, Grunke M, Dechant C, Reindl C, Kerzendorf U, Schulze-Koops H, et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum. 2010;62(10):2876–85.

28. Colombo E, Galli C, Erre GL, Piras C, Biondi G, Taras L, et al. Peripheral blood CD8+ T-cell profiles in patients with psoriatic arthritis: A cross-sectional case-control study. Eur Rev Med Pharmacol Sci. 2017;21(2):5166–71.

29. Diani M, Cacciano F, Manogiu L, Longhi M, Altomare A, Pigatto PD, et al. Increased frequency of activated CD8+ T cell effectors in patients with psoriatic arthritis. Sci Rep. 2019;9(1):1–10.

30. FitzGerald O, Haroon M, Giles JT, Winchester R. Concepts of pathogenesis in psoriatic arthritis: Genotype determines clinical phenotype. Arthritis Res Ther. 2015;17(1):1–11.

31. Hu S, Liang S, Guo H, Zhang D, Li H, Wang X, et al. Comparison of the inhibition mechanisms of Adalimumab and Infliximab in treating tumor necrosis factor α-associated diseases from a molecular view. J Biol Chem. 2013;288(38):27059–67.

32. Paul C. Ixekizumab or secukinumab in psoriasis: what difference does it make? Br J Dermatol. 2018;178(S):1003–5.

33. Dolcino M, Ottoria A, Barbieri A, Patuzzo G, Tinazzi E, Argentino G, et al. Gene expression profiling in peripheral blood cells and synovial membranes of patients with psoriatic arthritis. PLoS One. 2015;10(6):1–33.

34. Belasco J, Louie JS, Gulati N, Wei N, Nograles K, Fuentes-Duculan J, et al. Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis. Arthritis Rheum. 2015;67(4):934–44.

35. O’Brien-Gore C, Gray EH, Durham LE, Taams LS, Kirkham BW. Drivers of Inflammation in Psoriatic Arthritis: the Old and the New. Curr Rheumatol Rep. 2021;23(6):1–11.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.